[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fO36Z6NWs2E_fuAUHlX9ZiNpiO0aYjQgWccvN1fOPfGc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":38,"rows":45},"University Medical Center Goettingen",[4],59,false,22,1,23415,51,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"CMT (Charcot Marie Tooth Disease)",4,{"name":17,"count":18},"Acute Pancreatitis",3,{"name":20,"count":18},"Heart Failure",{"name":22,"count":18},"CMT",{"name":24,"count":18},"CMT - Charcot-Marie-Tooth Disease",{"name":26,"count":18},"CMT1A",{"name":28,"count":18},"Oral Health Care",{"name":30,"count":31},"Orofacial Pain",2,[33],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT04396899","Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure","2027-12","EHM implantation",[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,68,96,114,141,172,190,208,226,244,262,297,319,343],{"intervention":37,"totalTrials":9,"cells":47},{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":62,"PHASE4":64,"NA":66},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":9,"soonestReadout":36},[55],{"nctId":34,"briefTitle":35,"status":56,"phases":57,"primaryCompletion":36,"completion":36,"start":58,"enrollment":59,"conditions":60,"interventions":61},"RECRUITING",[40,41],"2020-02-03",53,[20],[37],{"trials":63,"activeCount":50},[],{"trials":65,"activeCount":50},[],{"trials":67,"activeCount":50},[],{"intervention":69,"totalTrials":9,"cells":70},"Spironolactone 25mg",{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":92,"NA":94},{"trials":72,"activeCount":50},[],{"trials":74,"activeCount":50},[],{"trials":76,"activeCount":50},[],{"trials":78,"activeCount":50},[79],{"nctId":80,"briefTitle":81,"status":82,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":90},"NCT05230901","Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden","UNKNOWN",[42],"2025-06","2026-03","2022-02-23",300,[89],"Aortic Stenosis, Severe",[69,91],"Dihydralazine",{"trials":93,"activeCount":50},[],{"trials":95,"activeCount":50},[],{"intervention":91,"totalTrials":9,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":110,"NA":112},{"trials":99,"activeCount":50},[],{"trials":101,"activeCount":50},[],{"trials":103,"activeCount":50},[],{"trials":105,"activeCount":50},[106],{"nctId":80,"briefTitle":81,"status":82,"phases":107,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":108,"interventions":109},[42],[89],[69,91],{"trials":111,"activeCount":50},[],{"trials":113,"activeCount":50},[],{"intervention":115,"totalTrials":9,"cells":116},"Fasudil",{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":118,"activeCount":50},[],{"trials":120,"activeCount":50},[],{"trials":122,"activeCount":50},[123],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"NCT03792490","Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS","COMPLETED",[41],"2022-11-30","2023-11-01","2019-02-20",120,[133],"Amyotrophic Lateral Sclerosis",[115],{"trials":136,"activeCount":50},[],{"trials":138,"activeCount":50},[],{"trials":140,"activeCount":50},[],{"intervention":142,"totalTrials":9,"cells":143},"Drug application Amitriptyline",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":145,"activeCount":50},[],{"trials":147,"activeCount":50},[148],{"nctId":149,"briefTitle":150,"status":126,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":158},"NCT02054299","Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1",[40],"2016-02","2013-04",48,[156,157],"Drug Metabolism","Membrane Transport",[142,159,160,161,162,163],"Drug application Desvenlafaxine","Drug application Sumatriptan","Drug application Proguanil","Drug application Fenoterol","Drug application Thiamine",{"trials":165,"activeCount":50},[],{"trials":167,"activeCount":50},[],{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[],{"intervention":159,"totalTrials":9,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":188},{"trials":175,"activeCount":50},[],{"trials":177,"activeCount":50},[178],{"nctId":149,"briefTitle":150,"status":126,"phases":179,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":180,"interventions":181},[40],[156,157],[142,159,160,161,162,163],{"trials":183,"activeCount":50},[],{"trials":185,"activeCount":50},[],{"trials":187,"activeCount":50},[],{"trials":189,"activeCount":50},[],{"intervention":160,"totalTrials":9,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":193,"activeCount":50},[],{"trials":195,"activeCount":50},[196],{"nctId":149,"briefTitle":150,"status":126,"phases":197,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":198,"interventions":199},[40],[156,157],[142,159,160,161,162,163],{"trials":201,"activeCount":50},[],{"trials":203,"activeCount":50},[],{"trials":205,"activeCount":50},[],{"trials":207,"activeCount":50},[],{"intervention":161,"totalTrials":9,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":224},{"trials":211,"activeCount":50},[],{"trials":213,"activeCount":50},[214],{"nctId":149,"briefTitle":150,"status":126,"phases":215,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":216,"interventions":217},[40],[156,157],[142,159,160,161,162,163],{"trials":219,"activeCount":50},[],{"trials":221,"activeCount":50},[],{"trials":223,"activeCount":50},[],{"trials":225,"activeCount":50},[],{"intervention":162,"totalTrials":9,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":242},{"trials":229,"activeCount":50},[],{"trials":231,"activeCount":50},[232],{"nctId":149,"briefTitle":150,"status":126,"phases":233,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":234,"interventions":235},[40],[156,157],[142,159,160,161,162,163],{"trials":237,"activeCount":50},[],{"trials":239,"activeCount":50},[],{"trials":241,"activeCount":50},[],{"trials":243,"activeCount":50},[],{"intervention":163,"totalTrials":9,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":260},{"trials":247,"activeCount":50},[],{"trials":249,"activeCount":50},[250],{"nctId":149,"briefTitle":150,"status":126,"phases":251,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":252,"interventions":253},[40],[156,157],[142,159,160,161,162,163],{"trials":255,"activeCount":50},[],{"trials":257,"activeCount":50},[],{"trials":259,"activeCount":50},[],{"trials":261,"activeCount":50},[],{"intervention":263,"totalTrials":31,"cells":264},"Arctuvan",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":287},{"trials":266,"activeCount":50},[],{"trials":268,"activeCount":50},[],{"trials":270,"activeCount":50},[],{"trials":272,"activeCount":50},[],{"trials":274,"activeCount":50},[275],{"nctId":276,"briefTitle":277,"status":126,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT03151603","Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial",[43],"2019-05-19","2019-06-20","2017-05-03",398,[284],"Urinary Tract Infections",[263,286],"Fosfomycin",{"trials":288,"activeCount":50},[289],{"nctId":290,"briefTitle":291,"status":126,"phases":292,"primaryCompletion":293,"completion":294,"start":281,"enrollment":282,"conditions":295,"interventions":296},"NCT03176563","Observational Follow-up Study of REGATTA",[],"2019-07-19","2019-08-20",[284],[263,286],{"intervention":286,"totalTrials":31,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":313},{"trials":300,"activeCount":50},[],{"trials":302,"activeCount":50},[],{"trials":304,"activeCount":50},[],{"trials":306,"activeCount":50},[],{"trials":308,"activeCount":50},[309],{"nctId":276,"briefTitle":277,"status":126,"phases":310,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":311,"interventions":312},[43],[284],[263,286],{"trials":314,"activeCount":50},[315],{"nctId":290,"briefTitle":291,"status":126,"phases":316,"primaryCompletion":293,"completion":294,"start":281,"enrollment":282,"conditions":317,"interventions":318},[],[284],[263,286],{"intervention":320,"totalTrials":9,"cells":321},"Proton pump inhibitor",{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":328,"PHASE4":330,"NA":332},{"trials":323,"activeCount":50},[],{"trials":325,"activeCount":50},[],{"trials":327,"activeCount":50},[],{"trials":329,"activeCount":50},[],{"trials":331,"activeCount":50},[],{"trials":333,"activeCount":50},[334],{"nctId":335,"briefTitle":336,"status":126,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":342},"NCT05817721","PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents",[],"2024-03-29","2023-05-05",893,[17],[320],{"intervention":344,"totalTrials":9,"cells":345},"Caffeine_TMS",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":347,"activeCount":50},[],{"trials":349,"activeCount":50},[],{"trials":351,"activeCount":50},[],{"trials":353,"activeCount":50},[],{"trials":355,"activeCount":50},[],{"trials":357,"activeCount":50},[358],{"nctId":359,"briefTitle":360,"status":126,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":368},"NCT03720665","Cortical Excitability Changes on the Sensorimotor Cortex Induced by Caffeine Consumption: A TMS Study",[44],"2019-11-18","2018-10-01",30,[366,367],"Cortical Excitability","Brain Stimulation",[344]]